1. Home
  2. AMGN
  3. AMGN News

Latest Amgen Inc. (AMGN) News on August 31, 2025

Does Imdelltra Royalty Deal Reinforce Royalty Pharma’s Long-Term Asset Strategy (RPRX)?
AMGN

Simply Wall St.

a day ago

Does Imdelltra Royalty Deal Reinforce Royalty Pharma’s Long-Term Asset Strategy (RPRX)?

AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE
AMGN

PR Newswire

2 days ago

AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE

Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill
AMGN

Insider Monkey

2 days ago

Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill

Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase
AMGN

Insider Monkey

2 days ago

Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase

AMGN

MT Newswires

2 days ago

DBS Bank Adjusts Amgen Price Target to $360 From $365, Maintains Buy Rating

Amgen partners with Veeva Systems to enhance clinical trial processes
AMGN

Clinical Trials Arena

2 days ago

Amgen partners with Veeva Systems to enhance clinical trial processes

AMGN

MT Newswires

3 days ago

Veeva Systems, Amgen Collaborate to Further Streamline Clinical Trials

Veeva Announces Collaboration with Global Biotech to Further Accelerate Clinical Trial Innovation
AMGN

PR Newswire

3 days ago

Veeva Announces Collaboration with Global Biotech to Further Accelerate Clinical Trial Innovation

2 Dividend Stocks to Hold for the Next 10 Years
AMGN

Motley Fool

3 days ago

2 Dividend Stocks to Hold for the Next 10 Years

Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic
AMGN

GlobeNewswire

4 days ago

Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic

Amgen (AMGN) Gains FDA Approval For Broadened Repatha® Use In Cardiovascular Risk Management
AMGN

Simply Wall St.

5 days ago

Amgen (AMGN) Gains FDA Approval For Broadened Repatha® Use In Cardiovascular Risk Management

AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?
AMGN

Zacks

5 days ago

AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?

Dow Loses About 350 Points After Record-Breaking Run
AMGN

The Wall Street Journal

6 days ago

Dow Loses About 350 Points After Record-Breaking Run

Royalty Pharma (RPRX) Acquires US$885 Million Royalty Interest In Amgen's Imdelltra
AMGN

Simply Wall St.

6 days ago

Royalty Pharma (RPRX) Acquires US$885 Million Royalty Interest In Amgen's Imdelltra

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
AMGN

Benzinga

6 days ago

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

AMGN

MT Newswires

6 days ago

Amgen Says US FDA Broadens Approved Use of Repatha

AMGN

MT Newswires

6 days ago

Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
AMGN

Zacks

6 days ago

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
AMGN

PR Newswire

6 days ago

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

AMGN

MT Newswires

6 days ago

Update: BeOne Medicines Sells Imdelltra Royalties to Royalty Pharma for Up to $950 Million

Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug
AMGN

Reuters

6 days ago

Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug

AMGN

MT Newswires

6 days ago

BeOne Medicines Sells Imdelltra Royalties to Royalty Pharma for Up to $950 Million

Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
AMGN

GlobeNewswire

6 days ago

Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
AMGN

Business Wire

6 days ago

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

AMGN

MT Newswires

6 days ago

Piper Sandler Adjusts Price Target on Amgen to $342 From $328, Maintains Overweight Rating

Investing in Amgen (NASDAQ:AMGN) three years ago would have delivered you a 35% gain
AMGN

Simply Wall St.

9 days ago

Investing in Amgen (NASDAQ:AMGN) three years ago would have delivered you a 35% gain

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
AMGN

Zacks

9 days ago

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment
AMGN

Exec Edge

9 days ago

ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
AMGN

GlobeNewswire

10 days ago

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?
AMGN

Zacks

10 days ago

Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?

SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM
AMGN

PR Newswire

10 days ago

SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM

Cytokinetics Names Jim Daly to Board of Directors
AMGN

GlobeNewswire

11 days ago

Cytokinetics Names Jim Daly to Board of Directors

AMGN

MT Newswires

11 days ago

Rothschild & Co Redburn Adjusts Price Target on Amgen to $180 From $185, Maintains Sell Rating

3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade
AMGN

Motley Fool

11 days ago

3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors
AMGN

Business Wire

12 days ago

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet
AMGN

Simply Wall St.

16 days ago

Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet

SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease
AMGN

Zacks

16 days ago

SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease

AMGN

MT Newswires

16 days ago

Daiwa Securities Adjusts Price Target on Amgen to $310 From $350, Maintains Outperform Rating

Why Amgen (AMGN) is a Top Value Stock for the Long-Term
AMGN

Zacks

17 days ago

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.'
AMGN

Investor's Business Daily

18 days ago

Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.'

AMGN

MT Newswires

18 days ago

Bernstein Adjusts Price Target on Amgen to $335 From $350

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
AMGN

GlobeNewswire

18 days ago

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB

5 Insightful Analyst Questions From Amgen’s Q2 Earnings Call
AMGN

StockStory

18 days ago

5 Insightful Analyst Questions From Amgen’s Q2 Earnings Call

AMGN Q2 Deep Dive: Volume Growth, Pipeline Progress, and Guidance Raise Meet Investor Skepticism
AMGN

StockStory

18 days ago

AMGN Q2 Deep Dive: Volume Growth, Pipeline Progress, and Guidance Raise Meet Investor Skepticism

Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise
AMGN

Pharma Voice

19 days ago

Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise

Amgen Announces Bemarituzumab’s Successful Phase 3 Results in FGFR2b+ Gastric Cancer
AMGN

Insider Monkey

19 days ago

Amgen Announces Bemarituzumab’s Successful Phase 3 Results in FGFR2b+ Gastric Cancer

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
AMGN

Zacks

20 days ago

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
AMGN

Zacks

20 days ago

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Amgen Insiders Sell US$12m Of Stock, Possibly Signalling Caution
AMGN

Simply Wall St.

20 days ago

Amgen Insiders Sell US$12m Of Stock, Possibly Signalling Caution

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
AMGN

Zacks

20 days ago

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.
AMGN

Barrons.com

20 days ago

Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.

Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season
AMGN

Zacks

23 days ago

Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season

AMGN

MT Newswires

24 days ago

HSBC Adjusts Amgen Price Target to $343 From $337, Maintains Buy Rating

Amgen (AMGN) Completes US$60,594 Million Share Buyback After 14 Years
AMGN

Simply Wall St.

24 days ago

Amgen (AMGN) Completes US$60,594 Million Share Buyback After 14 Years

Why S&P 500 Stock Amgen Stumbled Despite Its Beat-And-Raise Quarter
AMGN

Investor's Business Daily

25 days ago

Why S&P 500 Stock Amgen Stumbled Despite Its Beat-And-Raise Quarter

NRG Energy, Amgen, Arista Networks: Trending Tickers
AMGN

Yahoo Finance Video

25 days ago

NRG Energy, Amgen, Arista Networks: Trending Tickers

Amgen Stock Sinks As Market Eyes MariTide's Next Move
AMGN

Benzinga

25 days ago

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Teva’s Ajovy becomes first migraine prevention drug approved for children
AMGN

Pharmaceutical Technology

25 days ago

Teva’s Ajovy becomes first migraine prevention drug approved for children

AMGN

MT Newswires

25 days ago

UBS Cuts Price Target on Amgen to $317 From $326, Maintains Neutral Rating

Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly
AMGN

Zacks

25 days ago

Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly

AMGN

MT Newswires

25 days ago

Goldman Sachs Adjusts Amgen Price Target to $405 From $400, Maintains Buy Rating

AMGN

MT Newswires

25 days ago

Citigroup Adjusts Price Target on Amgen to $310 From $305, Maintains Neutral Rating

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
AMGN

CNW Group

25 days ago

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

AMGN

MT Newswires

25 days ago

Morgan Stanley Lifts Price Target on Amgen to $333 From $330, Keeps Equalweight Rating

Stocks to Watch Wednesday: Disney, AMD, Super Micro, Rivian
AMGN

The Wall Street Journal

25 days ago

Stocks to Watch Wednesday: Disney, AMD, Super Micro, Rivian

AMGN

MT Newswires

25 days ago

RBC Lifts Price Target on Amgen to $330 From $320, Keeps Outperform Rating

OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee
AMGN

GlobeNewswire

25 days ago

OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

Amgen Inc (AMGN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Robust Pipeline ...
AMGN

GuruFocus.com

25 days ago

Amgen Inc (AMGN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Robust Pipeline ...

Amgen’s (NASDAQ:AMGN) Q2: Beats On Revenue
AMGN

StockStory

25 days ago

Amgen’s (NASDAQ:AMGN) Q2: Beats On Revenue

Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic’s Scientific Advisory Board
AMGN

Business Wire

a month ago

Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic’s Scientific Advisory Board

Stocks Rise Pre-Bell Ahead of Latest Corporate Earnings; Investors Monitor Tariff Developments
AMGN

MT Newswires

a month ago

Stocks Rise Pre-Bell Ahead of Latest Corporate Earnings; Investors Monitor Tariff Developments

Global Markets Rise on Fed Rate-Cut Hopes
AMGN

The Wall Street Journal

a month ago

Global Markets Rise on Fed Rate-Cut Hopes

Cystinosis Global Market Research Report 2025-2035 | Orphan Drug Incentives, Innovative Cysteamine Delivery, Gene Therapy Potential, and Early Diagnosis Fueling Advancements
AMGN

GlobeNewswire

a month ago

Cystinosis Global Market Research Report 2025-2035 | Orphan Drug Incentives, Innovative Cysteamine Delivery, Gene Therapy Potential, and Early Diagnosis Fueling Advancements

Calcinosis Cutis Market Research Report 2025-2035 | Market Shifts Toward Targeted Therapies as Advances in Calcium Metabolism Research Drive Development of More Effective Treatments
AMGN

GlobeNewswire

a month ago

Calcinosis Cutis Market Research Report 2025-2035 | Market Shifts Toward Targeted Therapies as Advances in Calcium Metabolism Research Drive Development of More Effective Treatments

AMD & Pfizer earnings, ISM services data: What to Watch
AMGN

Yahoo Finance Video

a month ago

AMD & Pfizer earnings, ISM services data: What to Watch

Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
AMGN

Zacks

a month ago

Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
AMGN

Zacks

a month ago

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?

AMGN

MT Newswires

a month ago

Central Bank Outlook Lifts Wall Street Pre-Bell; Asia, Europe Up

AMGN

Argus Research

a month ago

Market Digest: TEVA, AMT, HOG, IEX, LMT, SPGI, PWR, XYL, LEA

Lilly’s Push to $1 Trillion Derailed by Trade Risks and Obesity Drug Speedbumps
AMGN

Bloomberg

a month ago

Lilly’s Push to $1 Trillion Derailed by Trade Risks and Obesity Drug Speedbumps

Do Wall Street Analysts Like Amgen Stock?
AMGN

Barchart

a month ago

Do Wall Street Analysts Like Amgen Stock?

Earnings To Watch: Amgen (AMGN) Reports Q2 Results Tomorrow
AMGN

StockStory

a month ago

Earnings To Watch: Amgen (AMGN) Reports Q2 Results Tomorrow

What To Expect in Markets This Week: Earnings From Palantir, AMD, McDonald’s and More
AMGN

Investopedia

a month ago

What To Expect in Markets This Week: Earnings From Palantir, AMD, McDonald’s and More

Amgen (AMGN) Board Declares US$2.38 Dividend for Q3 2025
AMGN

Simply Wall St.

a month ago

Amgen (AMGN) Board Declares US$2.38 Dividend for Q3 2025

McDonald’s, Palantir, Novo Nordisk Earnings: What to Watch Next Week
AMGN

The Wall Street Journal

a month ago

McDonald’s, Palantir, Novo Nordisk Earnings: What to Watch Next Week

AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
AMGN

PR Newswire

a month ago

AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND

What Trump's Big Pharma CEO letters mean for drug pricing power
AMGN

Yahoo Finance Video

a month ago

What Trump's Big Pharma CEO letters mean for drug pricing power

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
AMGN

Business Wire

a month ago

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS
AMGN

PR Newswire

a month ago

AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS

Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs
AMGN

The Wall Street Journal

a month ago

Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs

AMGN

Investing.com

a month ago

Trump demands pharma CEOs lower drug prices within 60 days

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
AMGN

Zacks

a month ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics
AMGN

Zacks

a month ago

Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics

With 81% institutional ownership, Amgen Inc. (NASDAQ:AMGN) is a favorite amongst the big guns
AMGN

Simply Wall St.

a month ago

With 81% institutional ownership, Amgen Inc. (NASDAQ:AMGN) is a favorite amongst the big guns

Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial
AMGN

Benzinga

a month ago

Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial

Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas
AMGN

GlobeNewswire

a month ago

Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas

Sicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health
AMGN

GlobeNewswire

a month ago

Sicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health

Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics
AMGN

GlobeNewswire

a month ago

Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics

UBS Raises PT on Amgen Inc. (AMGN) to $326 From $315, Keeps a Neutral Rating
AMGN

Insider Monkey

a month ago

UBS Raises PT on Amgen Inc. (AMGN) to $326 From $315, Keeps a Neutral Rating

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.
AMGN

Barrons.com

a month ago

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

Share on Social Networks: